突触囊泡蛋白 2A 作为突触病的潜在生物标志物。

Synaptic vesicle protein 2A as a potential biomarker in synaptopathies.

机构信息

Wallenberg Centre for Molecular and Translational Medicine, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Sweden; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; King's College London, Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical Neuroscience Institute, London, UK; NIHR Biomedical Research Centre for Mental Health & Biomedical Research Unit for Dementia at South, Maudsley NHS Foundation, London, UK.

出版信息

Mol Cell Neurosci. 2019 Jun;97:34-42. doi: 10.1016/j.mcn.2019.02.001. Epub 2019 Feb 20.

DOI:10.1016/j.mcn.2019.02.001

PMID:30796959

Abstract

Measuring synaptic density in vivo using positron emission tomography (PET) imaging-based biomarkers targeting the synaptic vesicle protein 2A (SV2A) has received much attention recently due to its potential research and clinical applications in synaptopathies, including neurodegenerative and psychiatric diseases. Fluid-based biomarkers in proteinopathies have previously been suggested to provide information on pathology and disease status that is complementary to PET-based measures, and the same can be hypothesized with respect to SV2A. This review provides an overview of the current state of SV2A PET imaging as a biomarker of synaptic density, the potential role of fluid-based biomarkers for SV2A, and related future perspectives.

摘要

目前，基于正电子发射断层扫描（PET）成像的突触小泡蛋白 2A（SV2A）靶向生物标志物来测量体内突触密度，因其在突触病（包括神经退行性和精神疾病）方面的潜在研究和临床应用而备受关注。先前有研究提出，在蛋白病中，基于液体的生物标志物可以提供与基于 PET 的测量互补的病理和疾病状态信息，SV2A 也可以假设如此。本综述概述了 SV2A PET 成像作为突触密度生物标志物的现状、SV2A 基于液体的生物标志物的潜在作用以及相关的未来展望。